Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 10/20 | 0.44 |
| ▸ | MC1R | Q01726 | 9/20 | 0.44 |
| ▸ | MC5R | P33032 | 1/20 | 0.35 |
| ▸ | MC3R | P41968 | 1/20 | 0.35 |
| ▸ | GGT1 | P19440 | 1/20 | 0.34 |
| ▸ | FPR1 | P21462 | 2/20 | 0.33 |
| ▸ | FPR2 | P25090 | 2/20 | 0.33 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.32 |
| ▸ | YAP1 | P46937 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20450409 | 0.94 | MC1R (0.48) | MC4RMC1RMC5RMC3RGGT1 | |
| SCHEMBL1311875 | 0.94 | MC1R (0.48) | MC4RMC1RMC5RMC3RGGT1 | |
| SCHEMBL2154173 | 0.90 | MC4R (0.45) | MC4RMC1RMC5RMC3R | |
| SCHEMBL20450420 | 0.88 | MC4R (0.49) | MC4RMC1RMC5RMC3RCYP51A1 | |
| SCHEMBL1311002 | 0.88 | MC4R (0.49) | MC4RMC1RMC5RMC3RCYP51A1 | |
| SCHEMBL2156021 | 0.87 | MC4R (0.49) | MC4RMC1RMC5RMC3R | |
| SCHEMBL2154522 | 0.87 | MC4R (0.45) | MC4RMC1RMC5RMC3RGGT1 | |
| SCHEMBL1309688 | 0.86 | MC1R (0.49) | MC4RMC1RMC5RMC3R | |
| SCHEMBL20450378 | 0.86 | MC1R (0.49) | MC4RMC1RMC5RMC3R | |
| SCHEMBL20450393 | 0.86 | MC4R (0.53) | MC4RMC1RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342194-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2011-07-13 | — | — | EP | disclosed |